ARK Genomic Revolution ETF (ARKG)

Cboe US Currently down 0.06 (-0.13%) in today's trading session

2 members of Congress have disclosed 13 trades in ARK Genomic Revolution ETF (ARKG) via STOCK Act filings. The most recent disclosure was a sale by Dwight Evans on 25 March 2022. The most active traders have been Angus King (8) and Dwight Evans (5). Aggregate disclosed activity totals roughly $8K in purchases and $64K in sales (midpoint estimates from bracketed disclosure amounts).

ARK Genomic Revolution ETF is currently trading at $47.14, positioned at 87% of its 52-week range ($24.60 – $50.53).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$47.14
24h Change
-0.06 (-0.13%)
52 Week Range
$24.60$50.53
View on NASDAQ

ARK Genomic Revolution ETF Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for ARKG

Select to highlight on chart
5 transactions
Compliance: 23%
Dwight Evans25 Mar 202225 Apr 2022SaleStock$1,001 - $15,000N/A
Dwight Evans25 Mar 202225 Apr 2022SaleStock$1,001 - $15,000N/A
Angus King16 Dec 202116 May 2022SaleStock$1,001 - $15,000N/A
Angus King16 Dec 202116 May 2022SaleStock$1,001 - $15,000N/A
Angus King16 Dec 202110 May 2023SaleStock$1,001 - $15,000N/A

See every trade

Sign in free to see the full trade history for this stock.

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$1.65B

Volume

1.45M

Beta

2.38

P/E Ratio

-

Fundamentals

EPS

-

Div. Yield

-

Open

$46.76

Day Range

$46.63 – $47.29

Company Information

Sector
Financial Services
Industry
Asset Management
Exchange
CBOE · USD
Country
US
IPO Date
2014-10-31

The ARKG fund operates as an actively managed Exchange Traded Fund (ETF), aiming to achieve significant capital appreciation over an extended period. Its investment strategy involves committing a minimum of 80% of its total assets, under typical mark...

No earnings data available for this stock.

Dividends

Dividend History

29 Dec 2021
Amount $0.3824
29 Dec 2020
Amount $0.7901
27 Dec 2019
Amount $1.0540
27 Dec 2018
Amount $0.4663
27 Dec 2017
Amount $0.3277

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

QLD

ProShares Ultra QQQ

55
$90.68+0.30 (+0.33%)
Financial Services
Held by same politician
Same sector: Financial Services
+1 more reason
1 politician
View Stock

JKE

iShares Morningstar Growth ETF

50
$283.81+1.35 (+0.48%)
Financial Services
Held by same politician
Same sector: Financial Services
+1 more reason
1 politician
View Stock

MUB

iShares National Muni Bond ETF

50
$104.03+0.03 (+0.03%)
Financial Services
Held by same politician
Same sector: Financial Services
+1 more reason
1 politician
View Stock

Frequently Asked Questions about ARKG

Which members of Congress have traded ARKG?
2 members of Congress have disclosed 13 trades in ARK Genomic Revolution ETF (ARKG) under the STOCK Act. The most active traders are Angus King and Dwight Evans.
When was ARKG most recently disclosed by Congress?
The most recent ARKG disclosure was a sale by Dwight Evans on 25 March 2022.
What is the total disclosed congressional trading volume for ARKG?
Members of Congress have disclosed approximately $8K in ARKG purchases and $64K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in ARKG?
This ARKG page updates as soon as new STOCK Act disclosures are filed for ARK Genomic Revolution ETF. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.